WILMINGTON, Del., February 05, 2026--(BUSINESS WIRE)--AOP Health US, LLC announced today that Rapiblyk® (landiolol) is now more widely available across the United States through contract with Vizient® ...
WILMINGTON, Del., April 15, 2026--(BUSINESS WIRE)--AOP Health US, LLC today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIBLYK® (landiolol) for use in pediatric patients ...
An infusion of landiolol does not reduce organ failure among patients with septic shock with tachycardia, according to a study published online Oct. 25 in the Journal of the American Medical ...
Researchers conducted a multicenter, randomized, open-label, controlled trial in 196 intensive care unit (ICU) adult patients with septic shock and persistent tachycardia at 20 sites in seven European ...
Please provide your email address to receive an email when new articles are posted on . Researchers evaluated randomized controlled trial data of esmolol and landiolol in adults with septic shock. The ...
VIENNA--(BUSINESS WIRE)--At the end of November 2023, AOP Orphan Pharmaceuticals GmbH (AOP Health), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health ...
Human heart, computer artwork. Landiolol is an ultra-short acting, cardioselective, beta-1 adrenoceptor blocker designed to reduce heart rate with a minimal effect over cardiac contractility. The New ...
Ultra-short acting and highly cardio-selective beta blocker Rapibloc® (Landiolol) receives regulatory approval in Europe. Rapibloc® (Landiolol) allows rapid control of heart rate with a ...
About The Study: The results of this randomized clinical trial involving 126 patients do not support the use of the very short-acting beta-blocker landiolol for managing patients with tachycardia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results